# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-183465
Filing Date
2026-04-28
Accepted
2026-04-28 06:50:13
Documents
16
Period of Report
2026-04-27

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | cgem-20260427.htm iXBRL | DEF 14A | 1115312
2 | GRAPHIC | img154183647_0.jpg | GRAPHIC | 31700
3 | GRAPHIC | img154183647_1.jpg | GRAPHIC | 31700
4 | GRAPHIC | img154183647_2.jpg | GRAPHIC | 1125602
5 | GRAPHIC | img154183647_3.jpg | GRAPHIC | 88625
| Complete submission text file | 0001193125-26-183465.txt |  | 5345930

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | cgem-20260427.xsd | EX-101.SCH | 11973
19 | EXTRACTED XBRL INSTANCE DOCUMENT | cgem-20260427_htm.xml | XML | 412601

Mailing Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 617-410-4650
Cullinan Therapeutics, Inc. (Filer) CIK: 0001789972 (see all company filings)

EIN.: 813879991 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39856 | Film No.: 26903049
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)